BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL

Georgia Greaves, Mateus Milani, Michael Butterworth, Rachel J. Carter, Dominic P. Byrne, Patrick A. Eyers, Xu Luo, Gerald M. Cohen, Shankar Varadarajan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The impressive selectivity and efficacy of BH3 mimetics for treating cancer has largely been limited to BCL-2 dependent hematological malignancies. Most solid tumors depend on other anti-apoptotic proteins, including MCL-1, for survival. The recent description of S63845 as the first specific and potent MCL-1 inhibitor represents an important therapeutic advance, since MCL-1 is not targeted by the currently available BH3 mimetics, Navitoclax or Venetoclax, and is commonly associated with chemoresistance. In this study, we confirm a high binding affinity and selectivity of S63845 to induce apoptosis in MCL-1-dependent cancer cell lines. Furthermore, S63845 synergizes with other BH3 mimetics to induce apoptosis in cell lines derived from both hematological and solid tumors. Although the anti-apoptotic BCL-2 family members in these cell lines interact with a spectrum of pro-apoptotic BH3-only proteins to regulate apoptosis, these interactions alone do not explain the relative sensitivities of these cell lines to BH3 mimetic-induced apoptosis. These findings necessitated further investigation into the requirement of BH3-only proteins in BH3 mimetic-mediated apoptosis. Concurrent inhibition of BCL-XL and MCL-1 by BH3 mimetics in colorectal HCT116 cells induced apoptosis in a BAX- but not BAK-dependent manner. Remarkably this apoptosis was independent of all known BH3-only proteins. Although BH3-only proteins were required for apoptosis induced as a result of BCL-XL inhibition, this requirement was overcome when both BCL-XL and MCL-1 were inhibited, implicating distinct mechanisms by which different anti-apoptotic BCL-2 family members may regulate apoptosis in cancer.

Original languageEnglish (US)
Pages (from-to)1037-1047
Number of pages11
JournalCell Death and Differentiation
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Pharmacology
Apoptosis
Proteins
Cell Line
Neoplasms
HCT116 Cells
Inhibition (Psychology)
Apoptosis Regulatory Proteins
Hematologic Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Greaves, G., Milani, M., Butterworth, M., Carter, R. J., Byrne, D. P., Eyers, P. A., ... Varadarajan, S. (2019). BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. Cell Death and Differentiation, 26(6), 1037-1047. https://doi.org/10.1038/s41418-018-0183-7

BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. / Greaves, Georgia; Milani, Mateus; Butterworth, Michael; Carter, Rachel J.; Byrne, Dominic P.; Eyers, Patrick A.; Luo, Xu; Cohen, Gerald M.; Varadarajan, Shankar.

In: Cell Death and Differentiation, Vol. 26, No. 6, 01.06.2019, p. 1037-1047.

Research output: Contribution to journalArticle

Greaves, G, Milani, M, Butterworth, M, Carter, RJ, Byrne, DP, Eyers, PA, Luo, X, Cohen, GM & Varadarajan, S 2019, 'BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL', Cell Death and Differentiation, vol. 26, no. 6, pp. 1037-1047. https://doi.org/10.1038/s41418-018-0183-7
Greaves, Georgia ; Milani, Mateus ; Butterworth, Michael ; Carter, Rachel J. ; Byrne, Dominic P. ; Eyers, Patrick A. ; Luo, Xu ; Cohen, Gerald M. ; Varadarajan, Shankar. / BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. In: Cell Death and Differentiation. 2019 ; Vol. 26, No. 6. pp. 1037-1047.
@article{3835cb5f56c74e25be85ecc042c00df7,
title = "BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL",
abstract = "The impressive selectivity and efficacy of BH3 mimetics for treating cancer has largely been limited to BCL-2 dependent hematological malignancies. Most solid tumors depend on other anti-apoptotic proteins, including MCL-1, for survival. The recent description of S63845 as the first specific and potent MCL-1 inhibitor represents an important therapeutic advance, since MCL-1 is not targeted by the currently available BH3 mimetics, Navitoclax or Venetoclax, and is commonly associated with chemoresistance. In this study, we confirm a high binding affinity and selectivity of S63845 to induce apoptosis in MCL-1-dependent cancer cell lines. Furthermore, S63845 synergizes with other BH3 mimetics to induce apoptosis in cell lines derived from both hematological and solid tumors. Although the anti-apoptotic BCL-2 family members in these cell lines interact with a spectrum of pro-apoptotic BH3-only proteins to regulate apoptosis, these interactions alone do not explain the relative sensitivities of these cell lines to BH3 mimetic-induced apoptosis. These findings necessitated further investigation into the requirement of BH3-only proteins in BH3 mimetic-mediated apoptosis. Concurrent inhibition of BCL-XL and MCL-1 by BH3 mimetics in colorectal HCT116 cells induced apoptosis in a BAX- but not BAK-dependent manner. Remarkably this apoptosis was independent of all known BH3-only proteins. Although BH3-only proteins were required for apoptosis induced as a result of BCL-XL inhibition, this requirement was overcome when both BCL-XL and MCL-1 were inhibited, implicating distinct mechanisms by which different anti-apoptotic BCL-2 family members may regulate apoptosis in cancer.",
author = "Georgia Greaves and Mateus Milani and Michael Butterworth and Carter, {Rachel J.} and Byrne, {Dominic P.} and Eyers, {Patrick A.} and Xu Luo and Cohen, {Gerald M.} and Shankar Varadarajan",
year = "2019",
month = "6",
day = "1",
doi = "10.1038/s41418-018-0183-7",
language = "English (US)",
volume = "26",
pages = "1037--1047",
journal = "Cell Death and Differentiation",
issn = "1350-9047",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL

AU - Greaves, Georgia

AU - Milani, Mateus

AU - Butterworth, Michael

AU - Carter, Rachel J.

AU - Byrne, Dominic P.

AU - Eyers, Patrick A.

AU - Luo, Xu

AU - Cohen, Gerald M.

AU - Varadarajan, Shankar

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The impressive selectivity and efficacy of BH3 mimetics for treating cancer has largely been limited to BCL-2 dependent hematological malignancies. Most solid tumors depend on other anti-apoptotic proteins, including MCL-1, for survival. The recent description of S63845 as the first specific and potent MCL-1 inhibitor represents an important therapeutic advance, since MCL-1 is not targeted by the currently available BH3 mimetics, Navitoclax or Venetoclax, and is commonly associated with chemoresistance. In this study, we confirm a high binding affinity and selectivity of S63845 to induce apoptosis in MCL-1-dependent cancer cell lines. Furthermore, S63845 synergizes with other BH3 mimetics to induce apoptosis in cell lines derived from both hematological and solid tumors. Although the anti-apoptotic BCL-2 family members in these cell lines interact with a spectrum of pro-apoptotic BH3-only proteins to regulate apoptosis, these interactions alone do not explain the relative sensitivities of these cell lines to BH3 mimetic-induced apoptosis. These findings necessitated further investigation into the requirement of BH3-only proteins in BH3 mimetic-mediated apoptosis. Concurrent inhibition of BCL-XL and MCL-1 by BH3 mimetics in colorectal HCT116 cells induced apoptosis in a BAX- but not BAK-dependent manner. Remarkably this apoptosis was independent of all known BH3-only proteins. Although BH3-only proteins were required for apoptosis induced as a result of BCL-XL inhibition, this requirement was overcome when both BCL-XL and MCL-1 were inhibited, implicating distinct mechanisms by which different anti-apoptotic BCL-2 family members may regulate apoptosis in cancer.

AB - The impressive selectivity and efficacy of BH3 mimetics for treating cancer has largely been limited to BCL-2 dependent hematological malignancies. Most solid tumors depend on other anti-apoptotic proteins, including MCL-1, for survival. The recent description of S63845 as the first specific and potent MCL-1 inhibitor represents an important therapeutic advance, since MCL-1 is not targeted by the currently available BH3 mimetics, Navitoclax or Venetoclax, and is commonly associated with chemoresistance. In this study, we confirm a high binding affinity and selectivity of S63845 to induce apoptosis in MCL-1-dependent cancer cell lines. Furthermore, S63845 synergizes with other BH3 mimetics to induce apoptosis in cell lines derived from both hematological and solid tumors. Although the anti-apoptotic BCL-2 family members in these cell lines interact with a spectrum of pro-apoptotic BH3-only proteins to regulate apoptosis, these interactions alone do not explain the relative sensitivities of these cell lines to BH3 mimetic-induced apoptosis. These findings necessitated further investigation into the requirement of BH3-only proteins in BH3 mimetic-mediated apoptosis. Concurrent inhibition of BCL-XL and MCL-1 by BH3 mimetics in colorectal HCT116 cells induced apoptosis in a BAX- but not BAK-dependent manner. Remarkably this apoptosis was independent of all known BH3-only proteins. Although BH3-only proteins were required for apoptosis induced as a result of BCL-XL inhibition, this requirement was overcome when both BCL-XL and MCL-1 were inhibited, implicating distinct mechanisms by which different anti-apoptotic BCL-2 family members may regulate apoptosis in cancer.

UR - http://www.scopus.com/inward/record.url?scp=85053057902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053057902&partnerID=8YFLogxK

U2 - 10.1038/s41418-018-0183-7

DO - 10.1038/s41418-018-0183-7

M3 - Article

C2 - 30185825

AN - SCOPUS:85053057902

VL - 26

SP - 1037

EP - 1047

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

SN - 1350-9047

IS - 6

ER -